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Abstract
Background: In the present study we tested the hypothesis that progression of streptozotocin
(STZ)-induced diabetes (14-days to 28-days) would produce renal and vascular dysfunction that
correlate with altered p38- mitogen-activated protein kinase (p38-MAPK) phosphorylation in
kidneys and thoracic aorta.
Methods: Male Sprague Dawley rats (350–400 g) were randomized into three groups: sham (N =
6), 14-days diabetic (N = 6) and 28-days diabetic rats (N = 6). Diabetes was induced using a single
tail vein injection of STZ (60 mg/kg, I.V.) on the first day. Rats were monitored for 28 days and food,
water intake and plasma glucose levels were noted. At both 14-days and 28-days post diabetes
blood samples were collected and kidney cortex, medulla and aorta were harvested from each rat.
Results: The diabetic rats lost body weight at both 14-days (-10%) and 28-days (-13%) more
significantly as compared to sham (+10%) group. Glucose levels were significantly elevated in the
diabetic rats at both 14-days and 28-days post-STZ administration. Renal dysfunction as evidenced
by renal hypertrophy, increased plasma creatinine concentration and reduced renal blood flow was
observed in 14-days and 28-days diabetes. Vascular dysfunction as evidenced by decreased carotid
blood flow was observed in 14-days and 28-days diabetes. We observed an up-regulation of
inducible nitric oxide synthase (iNOS), prepro endothelin-1 (preproET-1) and phosphorylated p38-
MAPK in thoracic aorta and kidney cortex but not in kidney medulla in 28-days diabetes group.
Conclusion: The study provides evidence that diabetes produces vascular and renal dysfunction
with a profound effect on signaling mechanisms at later stage of diabetes.
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Introduction
Diabetes is a complex and multifarious group of disorders
characterized by hyperglycemia that has reached epidemic
proportions in the present century. Infection is a leading
cause of morbidity and mortality among the diabetic pop-
ulation [1]. Diabetes is associated with vascular and renal
dysfunction characterized by hypertension, dyslipidemia,
microalbuminuria, macroalbuminuria and glomerular
mesangial expansion [2,3].
Mitogen-activated protein kinases (MAPKs) are impli-
cated in the etiology of diabetes [4,5]. MAPKs are serine-
threonine protein kinases involved in cell survival, prolif-
eration and apoptosis [6]. Three MAPK subfamilies have
been well characterized: extracellular signal regulated
kinase 1 and 2 (ERK1/2), c-jun N-terminal kinases (JNK)
and p38-MAPK [7]. ERK1/2 is involved in the growth
response of cell while p38-MAPK and JNK are associated
with cellular response to stress [7], inflammation [8] and
vasoactive mediators such as endothelin-1 (ET-1) [9]. Also
p38-MAPK activation stimulates inducible nitric oxide
synthase (iNOS) expression in serum-deprived RAW
264.7 cells [10]. These observations suggest that signaling
mechanisms can regulate various vasoactive molecules
and vice-versa. However it is still not known if progression
of diabetes produces a time dependent activation of p38-
MAPK in vascular blood vessels and kidneys. We speculate
a differential regulation of p38-MAPK and ERK1/2 in tho-
racic aorta and kidneys depending upon the duration and
severity of diabetes.
We have earlier demonstrated that diabetes during coro-
nary artery bypass grafting, and chronic peritoneal sepsis
produced an imbalance in the myocardial and systemic
ET-1 and nitric oxide (NO) profiles [11,12]. However, the
profile of ET-1 during progression of diabetes is unclear.
Diabetes, both type 1 and type 2, is associated with
decreased NO bioavailability [13,14]. Conflicting reports
(i.e. increased, unchanged and decreased) exist regarding
the state of inducible nitric oxide synthase (iNOS) and
endothelial NOS (eNOS) during diabetes [15,16]. We
have earlier reported that elevation of ET-1 and NO mech-
anisms, either systemically or locally in the myocardium,
correlated well with the development of myocardial dys-
function during sepsis [11] and make the heart suscepti-
ble to myocardial injury [17]. We anticipate that the
duration of hyperglycemia would differentially modulate
systemic and renal ET-1 and NO mechanisms.
We hypothesize that progression of diabetes [mild (14-
days) to moderate (28-days)] would produce renal and
vascular dysfunction that correlate with altered p38-
MAPK phosphorylation in kidneys and thoracic aorta.
Therefore, the specific aims of the study are to characterize
the progression of STZ-induced renal and vascular dys-
function at 14- and 28-days; and to examine if the pro-
gression of STZ-induced diabetes would alter the
biosynthesis and activation of ET-1, NO and the phospho-
rylation of p38-MAPK and ERK1/2 in thoracic aorta, kid-
ney cortex and kidney medulla.
Materials and methods
Male Sprague-Dawley rats (Harlan, Indianapolis, IN)
weighing 350–400 g were used in the study. The rats were
acclimatized to the laboratory conditions for at least 7
days following their arrival. All animal experiments were
conducted in compliance with humane animal care stand-
ards outlined in the NIH Guide for the Care and Use of
Experimental Animals, and were approved by the Institu-
tional Animal Care and Use Committee of North Dakota
State University.
Experimental Protocol
All animals were age-matched at the onset of the study.
The rats were randomly divided into three groups: con-
trol, 14-days and 28-days diabetic rats (n = 6 for each
group).
Induction of diabetes
Diabetes was produced by a single tail vein injection of
streptozotocin (STZ; 60 mg/kg, I.V.) [15]. Diabetes was
confirmed by blood glucose estimation (Glucometer
Elite®, Bayer Corporation, IN) 2 days after STZ-injection.
Diabetes was confirmed if blood glucose > 200 mg/dL.
The animals were not given insulin supplementation.
Food intake and water intake were examined everyday
after STZ-injection.
The non-diabetic control rats received an injection of 1
mL/kg saline. 14-days and 28-days post-STZ administra-
tion recordings of systemic hemodynamics, carotid blood
flow, and renal arterial blood were done. Arterial blood
was collected in plastic tubes containing EDTA (1 mg/mL)
and heparin (5 units/mL) to determine the plasma con-
centration of ET-1, NO by-products (NOx) and creatinine.
The animals were euthanitized by pentobarbital (100 mg/
kg, I.P.), the thoracic aorta and kidney were harvested. The
concentration of ET-1, NOx, creatinine and protein
expression of preproET-1, iNOS, eNOS, phosphorylated
p38-MAPK (pp38-MAPK), total p38-MAPK, phosphor-
ylated ERK, total ERK were determined in the thoracic
aorta, kidney cortex and kidney medulla obtained from
each animal.
Surgical protocol
Separate group of animals (N = 6) were used for hemody-
namic study. On the day of experiment, the rats were anes-
thetized with an intraperitoneal injection of pentobarbital
sodium (Nembutal®, Abbott; 50 mg/kg).
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Common carotid arterial blood flow measurement (acute)
Under pentobarbital (50 mg/kg I.P.) anesthesia, rats were
placed in dorsal recumbency and through a midline cervi-
cal incision, the left common carotid artery was identified
and carefully separated from adhering connective mate-
rial. The carotid artery was cleared from the vagal nerve
and a Transonic® flow probe (0.3 mm 1RB, Transonic Sys-
tems Inc., Ithaca, NY) was placed carefully around the
artery. The probe was manually positioned so that the
artery was centered within its window and then probe was
held in position. Through a sterile 10 CC syringe loaded
with sterile K-Y brand lubricating jelly (Johnson & John-
son, Arlington, TX), the acoustical window within the
flow probe was filled while avoiding any air bubble.
Renal arterial blood flow measurement (acute)
Under pentobarbital anesthesia, rats were place in dorsal
recumbency, and through a midline abdominal skin inci-
sion the left renal artery was carefully separated from renal
vein and a 0.5 VB Transonic® flow probe was placed
around it. The probe was manually positioned so that the
artery is centered within the window and the probe was
held in position. The acoustical window within the flow
probe was filled with K-Y brand lubricating jelly (Johnson
& Johnson, Arlington, TX). Renal and carotid artery blood
flow was measured using Transonic® flow meter T206
attached to MP100 system of Biopac Systems Inc., CA via
analog to digital conversion. The MP100 system was cali-
brated with minimum and maximum flow capacity of the
individual probe connected to the flow meter. The sam-
pling of data was carried out at 1000 Hz and recorded to
a dedicated computer using AcqKnowledge™ software.
Biochemical estimations
Determination of the concentration of plasma creatinine
The concentration of creatinine was determined in plasma
using creatinine liquid reagents (end-point, colorimetric,
DIAZYME). The blood samples immediately after collec-
tion were spun down at 5000 rpm for 10 minutes. The
plasma was then decanted and stored at -20°C until the
time of creatinine determination using manufacturer's
instruction. Plasma concentration of creatinine (mg.dL-
1.Kg-1) normalized to individual rat body weight was
calculated.
Determination of the plasma concentration of ET-1
The concentration of ET-1 was determined in plasma. The
blood samples were collected in plastic tubes containing
EDTA (1 mg/mL) before euthanasia. The sample was cen-
trifuged at 3,000 × g for 15 min at 4°C and plasma was
separated and assayed for ET-1. Plasma was acidified add-
ing an equal volume of 20% acetic acid. ET-1 like material
was extracted from plasma [11] using C-18 SEP-Columns
(Peninsula labs, CA). The recovery of ET from plasma was
approximately 87%. Immunoassay (IA) was performed
using EIA kit for ET-1 (R and D systems, Minneapolis,
MN). The assay was performed in microtiter plates coated
with a rat antibody to human ET-1. Diluted anti-ET-1 HRP
conjugate (100 µL) (ET-1 conjugated to horseradish per-
oxidase) was added in each well. Standards (0.25 pg – 65
pg ET-1), parameter control (24.5 ET-1 pg/ml) or sample
extract (100 µL, each) were added. The plates were cov-
ered with plate sealers and incubated for 1 hr at room tem-
perature. The contents of each well were aspirated and
washed using wash buffer provided with the kit. After the
last wash, contents of each well were decanted and tetram-
ethylbenzidine (100 µL) was added. After 30 min, stop
solution (100 µL) containing 1 N HCl was added. Within
30 min of addition of the stop solution, the optical den-
sity of each well was measured using a micro plate reader
at 450 (OD 450) and 620 (OD 620) nm separately. A
standard curve was created and the concentration of ET-1
of each sample calculated and expressed as pg/ml of
plasma.
Determination of the concentration of nitric oxide byproducts (NOx)
The concentration of endogenous NOX (nitrate + nitrite)
was determined in plasma, thoracic aorta, kidney cortex
and medulla. Blood (500 µL) was collected and 40 µL of
heparin was added to each sample to prevent clotting. The
blood sample was then decanted and stored at -20°C until
the time of nitric oxide byproducts, (NO2 + NO3) NOx,
determination. To determine the NOx level of thoracic
aorta, kidney cortex and kidney medulla, those tissue
samples were harvested from each experimental rat and
immediately homogenized with cold phosphate buffered
saline (PBS) on ice, which inhibited the activity of NOS ex
vivo. The homogenate was centrifuged (3000 × g, 5 min)
and the supernatant was collected. The supernatant
obtained from tissues and plasma was passed through a
1.2 µm multiscreen filter plate. Plasma NOx and tissue
NOx concentration was determined by using Greiss reac-
tion [11,15]. 6 µL of plasma was mixed with 44 µl distilled
H2O, 20 µl 0.31 M phosphate buffer (pH 7.5) and 10 µL
each of 0.86 mM NADPH (Sigma), 0.11 mM flavenidi-
nine dinucleotide and 1.0 U/mL of nitrate reductase. NO3
was converted to NO2 by nitrate reductase (Boehriger
Mannheim). Unknown tissue samples were run in dupli-
cate. The samples were allowed to incubate for 1 hr at
room temperature in the dark. Two hundred microliters of
Greiss reagent [1:1 mixture of 1% sulfanilamide in 5%
H3PO3 and 0.1% N-(1-naphthyl) ethyl-enediamine] were
added to each well and the plates were incubated for an
additional 10 min at room temperature. Absorbance was
measured at 540 nm using a plate reader and converted to
NOx concentration using a nitrate standard curve and
expressed as µM in plasma and µmoles/g protein in tissue.
Protein in the supernatant obtained from each sample
was determined using standard Lowry method.
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Immunoblot Analysis
PreproET-1, iNOS, eNOS, total and phosphorylated p38-
MAPK and ERK protein expressions of thoracic aorta, kid-
ney cortex and kidney medulla were determined using
standard SDS-PAGE and immunoblot technique. Briefly,
thoracic aorta, kidney cortex and kidney medulla tissues
were homogenized in lysis buffer and centrifuged as
described by Pollack et al. [16]. The supernatants, at a
final protein content of 25 µl, were loaded to the gels
using a 2:1 laemmli sample buffer (62.5 mM Tris-HCl, pH
6.8, 25% glycerol, 2% SDS, 0.01% bromophenol blue and
710 mM β-mercaptoethanol). The prepared samples were
electrophoresed on 10% denaturing sodium dodecyl sul-
fate (SDS) polyacrylamide gels. The proteins were trans-
ferred electrophoretically onto polyvinylidene difluoride
(PVDF) membrane (Gelman Sciences, Pierce, Rockford,
IL). Non-specific binding sites on the membrane were
blocked overnight at 4°C with 5% nonfat dry milk in Tris-
buffered saline containing Tween 20 (TBST, 20 mM Tris-
HCl, 150 mM NaCl, 0.2% Tween 20, pH 7.4). The mem-
branes were then probed with the primary antibody
(Santa Cruz Biotechnology, Santa Cruz, CA) for 1 hr at
room temperature. The primary antibodies are highly spe-
cific against the proteins studies and had no cross-reactiv-
ity with related members. After five washings in TBST, the
membranes were incubated with the secondary antibody
(Sigma, St. Louis, MO) for 1 hr at room temperature.
Finally membranes were washed three times with TBST.
The specific proteins were detected by enhanced chemilu-
minescence (ECL) reagent (Amersham Pharmacia Bio-
tech). The blots were analyzed using Un-Scan-It™ software
to estimate the density of the blots in pixels. Uniform
loading was assessed by β-actin (Sigma) protein expres-
sion. While analyzing the data for immunoblot analysis,
the beta-actin blots for each gel were analyzed first to con-
firm equal protein loading. Only after confirming that
there was equal protein loading in the wells, as evidenced
by no significant difference in pixel values of beta-actin
blots, the bands for individual proteins were analyzed.
Statistical Analyses
All the data were expressed as mean ± SEM. One-way
ANOVA was performed to analyze the hemodynamic and
biochemical data using SPSS software. Following a signif-
icant F value, a post hoc Students Newman Keuls test was
performed for inter- and intra-group comparisons. Statis-
tical significance was realized at p ≤ 0.05 to approve the
null hypothesis for individual parameters.
Results
General characteristics of the animals
All control rats were freely moving in their individual
cages through out the study. Although diabetic rats
appeared to be lethargic and displayed restricted move-
ments, there was no sign of infection or motor disorder in
any of the rats studied. The food intake and water intake
of 14-days and 28-days diabetes groups were significantly
increased as compared to control group (Fig 1).
The average body weight change, blood glucose and kid-
ney weight/ 100 g body weight in all groups are summa-
rized in Table 1. The body weight change (%) was
significantly decreased in 14-days and 28-days diabetes
groups as compared to their age-matched control group.
All STZ-treated rats were diabetic with mean blood glu-
cose around 480 mg/dL. Blood glucose was significantly
elevated in 14-days diabetes and 28-days diabetes groups
as compared to their age-matched control group. Kidney
weight normalized to body weight was significantly
greater in diabetic (14-days and 28-days) rats than in con-
trol rats. Plasma creatinine concentration was increased 3-
fold in 14-days diabetes group and 2-fold in 28-days dia-
betes group as compared to control group (Table 1). Dia-
betes (14- and 28-days) produced no significant change in
mean arterial pressure but caused a significant decrease in
heart rate (Table 1).
Effect of STZ-induced diabetes on aortic and renal blood 
flow
Control groups exhibited aortic and renal blood flow 10.8
± 0.3 mL/min and 5.4 ± 0.1 mL/min, respectively. Induc-
tion of diabetes produced a significant decrease in renal
(Fig 2A) and carotid blood flow (Fig 2B) at both 14-days
and 28-days as compared to control group.
Effect of STZ-induced diabetes on the concentration of 
ET-1 in plasma and expression of preproET-1 in thoracic 
aorta, kidney cortex and medulla
To determine the effect of duration of diabetes (14-days to
28-days) on aortic and renal ET-1 biosynthesis we deter-
mined the concentration of ET-1 in plasma and expres-
sion of ET-1 precursor, preproET-1 in thoracic aorta,
kidney cortex and kidney medulla. A significant elevation
in plasma ET-1 concentration was observed in 28-days
diabetes as compared to 14-days diabetes and control
groups (Fig 3A). We did not find any significant change in
the plasma concentration of ET-1 in 14-days diabetes
group as compared to control group. The expression of
preproET-1 was significantly increased in thoracic aorta in
14-days and 28-days diabetes groups as compared to con-
trol group (Fig 3B). We also found a significant increase in
the expression of preproET-1 in kidney cortex in 14-days
diabetes groups as compared to control group. A signifi-
cant increase in the protein expression of preproET-1 of
kidney cortex was observed in 28-days diabetes group as
compared to 14-days diabetes and control groups (Fig
3C). Induction of diabetes did not produce any change in
the expression of preproET-1 in kidney medulla at 14-
days and 28-days diabetes groups as compared to control
group (Fig 3D).
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Effect of STZ-induced diabetes on the concentration of 
NOx and expression of eNOS and iNOS
A significant increase in the concentration of NOx in
plasma of 28-days diabetes group as compared to the con-
trol and 14-days diabetes groups was observed (Fig 4A).
The NOx level was also elevated in thoracic aorta of 28-
days diabetes group as compared to the control and 14-
days diabetes groups (Fig 4B). In kidney cortex, we also
found that NOx level was significantly increased in 14-
days and 28-days diabetes groups as compared to control
group (Fig 4C). But we did not find any significant change
in kidney medulla of 14-days and 28-days diabetes groups
(Fig 4D).
A significant up-regulation of eNOS and iNOS in thoracic
aorta in 14-days and 28-days diabetes groups was
obtained as compared to control group (Fig 5A1–A3).
Also in kidney cortex in 28-days diabetes, eNOS and iNOS
were significantly increased as compared to 14-days dia-
betes and control groups. Protein expression of iNOS was
also significantly increased in kidney cortex in 14-days
diabetes group as compared to control group (Fig 5B1–
B3). In kidney medulla we did not find any significant
change in eNOS and iNOS in 14-days and 28-days diabe-
tes groups as compared to control group (Fig 5C1–C3).
Effect of STZ-induced diabetes on the expression of total 
and phosphorylated p38-MAPK and ERK1/2 in thoracic 
aorta, kidney cortex and medulla
Total p38-MAPK and phosphorylated p38-MAPK protein
expressions in thoracic aorta were significantly elevated in
14-days and 28-days diabetes groups as compared to con-
trol group (Fig 6A1–A3). Expression of phosphorylated
p38-MAPK was significantly increased in kidney cortex
obtained from 28-days diabetes group as compared to 14-
days diabetes and control groups. Total p38-MAPK was
not altered in kidney cortex in 14-days and 28-days diabe-
tes groups as compared to control group (Fig 6B1–B3). In
kidney medulla of 14-days and 28-days diabetes groups
we did not observe any significant change in total and
phosphorylated p38-MAPK (Fig 6C1–C3).
A significant decrease in the expression of phosphorylated
ERK 1/2 of thoracic aorta in 28-days diabetes group but
not in 14-days diabetes group was observed as compared
to control group. We found that total ERK 2 but not total
ERK 1 was significantly increased in thoracic aorta in 14-
days diabetes groups as compared to control group. There
was no change in the expression of total ERK 1 in 14-days
Table 1: Effect of STZ-induced diabetes on percent body weight (BW) change, blood glucose levels (mg.dL-1), mean arterial pressure 
(mmHg), heart rate (beats per min), kidney weight/100 g BW, and plasma creatinine concentration (g.dL-1.kg-1 BW) at 14-days (Diab, 
14-days) and 28-days (Diab, 28-days). (N = 6 in each group) * p ≤ 0.05 Vs control group.
Parameter Control Diab (14-days) Diab (28-days)
BW change (%) 10 ± 3 -10 ± 3* -13 ± 2*
Blood glucose (mg.dL-1) 84 ± 2 480 ± 3* 486 ± 11*
Mean arterial pressure (mmHg) 130 ± 3 120 ± 6 117 ± 2
HR (Beats per min) 419 ± 5 326 ± 7* 339 ± 10*
Kidney weight/100 g BW 0.72 ± 0.03 1.1 ± 0.05* 1.0 ± 0.03*
Plasma creatinine (mg.dL-1.kg-1) 2.4 ± 0.5 6.4 ± 3.5 4.5 ± 3.5
Renal blood flow (mL/min) (A) and carotid blood flow (mL/mi ) (B) in control, 14-days and 28-d ys STZ-in uced diabe-tes groups (N = 6 in each group); * p ≤ 0.05 Vs control groupFigu e 2
Renal blood flow (mL/min) (A) and carotid blood flow (mL/
min) (B) in control, 14-days and 28-days STZ-induced diabe-
tes groups (N = 6 in each group); * p ≤ 0.05 Vs control 
group.
(A)
(B)
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and 28-days diabetes groups and ERK 2 in 28-days diabe-
tes group as compared to control group (Fig 7A1–A3). In
kidney cortex phosphorylated ERK 1/2 protein expression
was significantly elevated in 28-days diabetes group as
compared to 14-days diabetes and control groups. In kid-
ney cortex, phosphorylated ERK 1/2 was significantly ele-
vated in 14-days diabetes group as compared to control
group. Total ERK 1/2 was not altered in kidney cortex in
14-days and 28-days diabetes groups (Fig 7B1–B3). In
addition, in kidney medulla we did not observe any sig-
nificant change in total and phosphorylated ERK 1/2 in
14-days and 28-days diabetes group as compared to con-
trol group (Fig 7C1–C3).
Discussion
STZ has long been used as a drug of choice to induce type
2 diabetes in various animal models. This well-established
model is characterized by insulin deficiency associated
with insulin resistance [18]. It was reported that a single
intravenous injection of STZ (55 mg/kg) could cause
increased plasma glucose levels, decrease in body weight
and 17% mortality in rats [18]. In the present study, too,
we have observed a mortality of 20% in 14-days diabetes
group and 26% in 28-days diabetes group. STZ-treated
rats, post 48-h, were confirmed to be hyperglycemic, lost
body weight 10% and 13% in 14-days and 28-days diabe-
tes groups respectively. Kavalali et al. [19] found that food
and water intake amount was higher in diabetic groups
The concentration of plasma ET-1 (pg.mL-1) in control, 14-days and 28-days STZ-induced diabetes groups (A) (N = 6 in each group)Fig re 3
The concentration of plasma ET-1 (pg.mL-1) in control, 14-days and 28-days STZ-induced diabetes groups (A) (N = 6 in each 
group). Effect of duration (14-days and 28-days) of STZ-induced diabetes on the expression of preproET-1 protein in thoracic 
aorta (B), in kidney cortex (C) and in kidney medulla (D) and % change in densitometric units of preproET-1 (N = 3 in each 
group); * p ≤ 0.05 Vs control group, # p ≤ 0.05 Vs 14-days diab group.
(C) Kidney cortex
(A) (B) Aorta
(D) Kidney medulla
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than the control group. In our study too, we observed that
diabetic rats had an increase in the food intake and water
intake following 14-days and 28-days of STZ-administra-
tion. These observations suggested that single intravenous
injections of STZ (60 mg/kg) produced a reproducible and
consistent model of diabetes in our laboratory conditions.
Renal hypertrophy can be detected as early as one day
after the onset of diabetes and seen regularly post 60-hr of
single STZ injection [20]. It has been reported that diabe-
tes-induced renal hypertrophy produces increased dimen-
sions of renal cells along with increased kidney weight
[21]. In the present study, we observed an elevated kidney
weight corrected by body weight in diabetic (14-days and
28-days) rats suggesting that STZ-induced diabetes pro-
duced renal hypertrophy. We also observed that both 14-
and 28-days diabetic rats exhibited reduced renal blood
flow along with 3-2 fold increase in plasma creatinine
concentration. Umerani and Goyal [22] demonstrated an
increase in serum creatinine as an indicator of deterio-
rated renal function in diabetic rats. Similar to our results,
Itoh and coworkers [23] also demonstrated that serum
creatinine levels in control group and diabetes group var-
ied from 0.8 to 1.4 mg/dl respectively. Thus the results
obtained in our study provide evidence for diabetes-
induced renal dysfunction in the rat.
Effect of STZ-induced diabetes on the plasma (A), thoracic aorta (B), kidney cortex (C) and kidney medulla (D) concentration o  nitric oxide bypro ucts (NOx) in control, 14-days and 28-days diabetic ratsFigu e 4
Effect of STZ-induced diabetes on the plasma (A), thoracic aorta (B), kidney cortex (C) and kidney medulla (D) concentration 
of nitric oxide byproducts (NOx) in control, 14-days and 28-days diabetic rats. (N = 6 in each group); * p ≤ 0.05 Vs control 
group, # p ≤ 0.05 Vs 14-days diab group.
(A) (B)
(C) (D)
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ET-1, a potent vasoconstrictor peptide, has been impli-
cated in diabetes and cardiovascular disorders. Elevated,
unchanged and attenuated plasma ET-1 levels have been
reported during diabetes [24-27]. Although the reason for
such a variation in findings appears difficult to fathom,
the discrepancies in data may be attributed to differences
in species of animals, duration of hyperglycemia, dose of
STZ administered etc. In the present study, we observed
decreased aortic and renal blood flow in both 14-days and
28-days diabetics rats. However elevation of ET-1 and
NOx in plasma was seen only in 28-days diabetic rats
group but not in 14 days-diabetes group. Taken together,
these observations suggest that STZ-induced hyperglyc-
emia produced alterations in the systemic and regional
blood flow, which could be due to altered systemic levels
of ET-1 and NO. Makino et al. [27] demonstrated upregu-
lated preproET-1 mRNA in the aorta from STZ-induced
diabetic rats. They suggested that increased release of ET-1
from the aorta contributes to enhanced plasma level of
ET-1 seen in diabetic rats. Also ET-1 concentration has
been shown to increase in kidneys [28] following diabe-
tes. Since ET-1 exists not only in the vascular endothelial
cells but also in the mesangial cells or tubular cells, this
increase in ET-1 could be attributed to increased biosyn-
thesis of ET-1 in the renal cells [28-30]. In the present
study, we also observed an elevated expression of pre-
proET-1 proteins in aorta and kidney cortex but not in
kidney medulla at 14-days and 28-days following diabetes
Effect of STZ-induced diabetes on the protein expression of iNOS and eNOS in thoracic aorta obtained from control, 14-days and 28-days d abetic ratsFigure 5
Effect of STZ-induced diabetes on the protein expression of iNOS and eNOS in thoracic aorta obtained from control, 14-days 
and 28-days diabetic rats. Representative protein expression of inducible- and endothelial-NOS (A1), % change in densitomet-
ric units of eNOS (A2) and iNOS (A3) in aorta, eNOS (B2) and iNOS (B3) in kidney cortex and eNOS (C2) and iNOS (C3) in 
kidney medulla. (N = 3 in each group); * p ≤ 0.05 Vs control group, # p ≤ 0.05 Vs 14-days diab group.
Aorta Kidney cortex Kidney medulla
(A2)
(A3)
(A1) (C1)(B1)
(B2)
(B3)
(C2)
(C3)
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induction. These findings suggest that during early diabe-
tes an upregulation of ET-1 biosynthesis in vascular (tho-
racic aorta) and locally at the organ level (kidney cortex)
could be responsible for vascular and renal dysfunction
seen during diabetes. Although the mechanisms of ET-1
elevation during diabetes are relatively unknown, several
research groups speculated that this increase could be due
to an abnormal production by the affected endothelium
[31] or lack of suppression of ET-1 release secondary to
attenuated endothelium-derived relaxing factor produc-
tion [32].
Hirata et al. demonstrated that ET-1 via binding to ETB
receptors produces activation of NOS [33] and generates
NO. In the present study, elevated concentration of NOx
in plasma, thoracic aorta and kidney cortex but not in
medulla was observed in 28-days diabetes group.
Stockklauser-Farber et al. [7] demonstrated an increased
myocardial NOS (iNOS and eNOS) activity that reached
maximal values after 4 wk and 6 wk diabetes. We specu-
lated that along with elevated NO production, activation
of NOS isoforms may play a prominent role in the patho-
physiology of nephropathy at different phases of STZ-
Effect of STZ-induced diabetes on the protein expression of total and phosphorylated p38-MAPK in thoracic aorta obtained from c ntrol, 14-days and 28-days diabetic ratsFigure 6
Effect of STZ-induced diabetes on the protein expression of total and phosphorylated p38-MAPK in thoracic aorta obtained 
from control, 14-days and 28-days diabetic rats. Representative protein expression of phospho- and total- p38-MAPK (A1, B1 
and C1), % changes in densitometric units of phospho-p38-MAPK (A2, B2 and C2) and total-p38-MAPK (A3, B3 and C3) in 
aorta, kidney cortex and kidney medulla respectively. (N = 3 in each group); * p ≤ 0.05 Vs control group, # p ≤ 0.05 Vs 14-days 
diab group.
Aorta Kidney cortex Kidney medulla
(A2)
(A3)
(A1) (C1)(B1)
(B2)
(B3)
(C2)
(C3)
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induced diabetes [34,35]. Increased expression of eNOS
in afferent arterioles and glomeruli was found by Sugim-
oto et al. [36]. In a previous study, these authors demon-
strated an enhanced renal expression of iNOS 5 days post
diabetes that was sustained for 20 days, while eNOS and
nNOS were not altered [37]. We also observed that the
progression of diabetes from 14-days to 28-days upregu-
lated iNOS and eNOS in thoracic aorta and kidney cortex
while decreasing aortic and renal blood flow that corre-
lated well with systemic and local increase in NOx levels
in thoracic aorta. This suggests that NO stimulation in
thoracic aorta and kidney cortex occurs with increased
duration of hyperglycemia in STZ-induced diabetic rats.
Since in the present study both ET-1 and NOS activation
exhibit a similar course in 28-days diabetic rats, we specu-
late that NOS stimulation could be due to activation of
ETB receptors via elevated ET-1 mechanisms. However,
further studies will be required to strengthen this
speculation.
Signaling mechanisms in diabetes
Hyperglycemia has been shown to phosphorylate ERK1/2
in rat glomerular and mesangial cells [38] and p38-MAPK
in vascular smooth muscle cells and aorta in derived from
diabetic rats [39]. Pearson et al. [40] and Tian et al. [41]
demonstrated that ET-1 stimulation of mesangial cell
(MC) proliferation involves several pathways, among
which MAPK figures prominently. In the present study, we
Effect of STZ-induced diabetes on the protein expression of total and phosphorylated ERK 1/2 in thoracic aorta obtained from control, 14-days and 28-days diabetic ratsFigure 7
Effect of STZ-induced diabetes on the protein expression of total and phosphorylated ERK 1/2 in thoracic aorta obtained from 
control, 14-days and 28-days diabetic rats. Representative protein expression of phospho- and total-ERK (A1, B1 and C1), % 
changes in densitometric units of p-ERK (A2, B2 and C2) and Total-ERK (A3, B3 and C3) in aorta, kidney cortex and kidney 
medulla respectively. (N = 3 in each group); * p ≤ 0.05 Vs control group, # p ≤ 0.05 Vs 14-days diab group.
Aorta Kidney cortex Kidney medulla
(A2)
(A3)
(A1) (C1)(B1)
(B2)
(B3)
(C2)
(C3)
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observed that 14-days diabetes up-regulated phosphor-
ylated p38-MAPK but not ERK1/2 in thoracic aorta. We
also observed down-regulation of phosphorylated ERK 1/
2 in thoracic aorta post 28-days diabetes. In kidney cortex
although p38-MAPK was not altered post 14-days diabetic
group, ERK1/2 is elevated. This suggests that ERK1/2
phosphorylation predominate during 14-days diabetes in
kidney cortex but not in thoracic aorta, while both p38-
MAPK and ERK1/2 remain unaffected in kidney medulla.
Both in vivo and in vitro results suggest that ERK and
p38MAPK may be involved in high-glucose-induced cel-
lular hypertrophy [42]. In the present study, we observed
that ERK1/2 precedes p38-MAPK phosphorylation
depending upon the progression of diabetes from 14-days
to 28-days. We observed a profound increase in plasma
NOx levels and iNOS expression with a corresponding
increase in p38-MAPK activation in kidney cortex and tho-
racic aorta during 28-days diabetes. We propose that p38-
MAPK activation could be an important signaling mecha-
nism that causes iNOS activation as was reported by Liu et
al. [14]. We speculate that activated p38-MAPK and iNOS
mechanisms outweigh ERK1/2 mechanisms in kidney
cortex and thoracic aorta during moderate diabetes. A
similar finding, though not directly related to the present
study, was shown by Purves et al. [43] where they
demonstrated using cultured sensory neurons that co-
treatment with high glucose and oxidative stress results in
an additive effect on p38-MAPK phosphorylation without
affecting ERK1/2 activation. The findings of the present
study suggested that phosphorylation of p38-MAPK and
not ERK1/2 was associated with iNOS activation and renal
and vascular dysfunction following 28-days of STZ-
induced hyperglycemia.
The results obtained in the present study characterize the
STZ (60 mg/kg, I.V.)-induced diabetic rat model in our
laboratory. The marked characteristics of diabetic rat
model include weight loss, increase food and water
intake, and bradycardia. STZ-induced diabetes, both at
14-days and 28-days, produced renal dysfunction and vas-
cular dysfunction that correlated well with levels of ET-1
and NOx and expression of preproET-1 and NOS proteins
in kidney cortex and thoracic aorta. The data obtained in
the present study demonstrate that progression of diabe-
tes from 14-days to 28-days caused a factorial increase in
p38-MAPK phosphorylation along with NOS upregula-
tion in kidney cortex and thoracic aorta. The study
provides evidence that diabetes produces vascular and
renal dysfunction with a profound effect on signaling
mechanisms at later stage of diabetes. However, more
studies will be required to further delineate the inherent
link or interaction between p38-MAPK upregulation, ET-1
and NO mechanisms and development of renal and vas-
cular dysfunction during diabetes.
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